Drugs / PEGMUSIRUDIN
PEGMUSIRUDIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00074620 | Nov 2003 → Jan 2006 | chronic renal failure syndrome, vascular occlusion disorder | Speedel Pharma Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGMUSIRUDIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108753 ↗ |
| Known as | PEG-hirudin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00074620 ↗ |
| Known as | Peg-hirudin (spp200) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108753 ↗ |
| Known as | Pegmusirudina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108753 ↗ |
| Known as | Pegmusirudine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108753 ↗ |
| Known as | SPP200 | “A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis” NCT00074620 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108753 ↗ |